Bris­tol My­ers flunks front­line mul­ti­ple myelo­ma tri­al, turn­ing at­ten­tion to cell ther­a­py

Cel­gene and Bris­tol My­ers Squibb may have com­bined forces, but their lat­est mix of mul­ti­ple myelo­ma treat­ments don’t ap­pear to be a good match.

Bris­tol My­ers an­nounced that its Phase III tri­al com­bin­ing the BMS drug Em­plic­i­ti — co-de­vel­oped with Ab­b­Vie — with Cel­gene’s long-run­ning block­buster Revlim­id had failed. The cock­tail did not help first-line pa­tients hold off can­cer pro­gres­sion for longer than just Revlim­id alone. (Both treat­ment arms were al­so giv­en the steroid dex­am­etha­sone.)

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER